News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
PreClin VCN-12 Data@ESGCT
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Healthcare
Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a…
Partners - THERIVA BIOLOGICS S.L.
PCB imagen recurso
Public research at the Barcelona Science Park – UB reaches a record investment of €84 million in 2024
Healthcare
The public research institutes, together with the units and groups of the University of Barcelona (…
Partners - Parc Científic de Barcelona
Sede Natac
Natac records revenues of €31.88 million through mid-October
Healthcare
The company expects to close the year with sales exceeding €50 million and an EBITDA above €20…
Partners - Natac Group
Asabys co-lidera la Series B de Qida de €37M
Qida raises €37 million to continue improving the quality of life of the senior segment at home
Financing
The investment will enable Qida to boost growth, technological innovation, and the attraction of…
Partners - Asabys Partners
Imagen recurso de unos pulmones
BCN HEALTH publica un estudio evaluando la incidencia y el coste de la enfermedad renal crónica en España
Healthcare
BCN HEALTH has published in the Journal of Medical Economics a study analyzing the incidence,…
Partners - BCN Health
oryzon
ORYZON announces First‑Patient‑In (FPI) in RESTORE Phase Ib trial of iadademstat in sickle cell disease
Healthcare
Recently approved by the European Medicines Agency, RESTORE will evaluate iadademstat’s ability to…
Partners - Oryzon Genomics
AptaTargets Merck
GENESIS Biomed participated in the strategic development of AptaTargets, which has licensed its drug ApTOLL to Merck
Access to innovation · Financing
AptaTargets signed in May 2025 a licensing agreement with Merck for the clinical development and…
Partners - GENESIS Biomed
Fachada de las oficinas de Oryzon Genomics
ORYZON to participate in upcoming events in November
Corporate
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company and global leader in epigenetics…
Partners - Oryzon Genomics
Inhibitec
When biotechnology puts itself in the patient’s skin
Healthcare · Access to innovation · Innovative drugs
The biotech company Inhibitec is advancing the development of an antibody targeting the BAMBI…
AseBio - Inhibitec Anticuerpos